Cdx2 is an intestine-specific transcription factor known to regulate proliferation and differentiation. We have reported previously that Cdx2 limits the proliferation of human colon cancer cells by inhibiting the transcriptional activity of the b-catenin-T-cell factor (TCF) bipartite complex. Herein we further elucidate this mechanism. Studies with a classic Cdx2 target gene and a canonical Wnt/b-catenin/TCF reporter suggest that Cdx2 regulates these promoters by distinctly different processes. Specifically, inhibition of b-catenin/TCF activity by Cdx2 does not require Cdx2 transcriptional activity. Instead, Cdx2 binds b-catenin and disrupts its interaction with the DNA-binding TCF factors, thereby silencing b-catenin/TCF target gene expression. Using Cdx2 mutants, we map the Cdx2 domains required for the inhibition of b-catenin/TCF activity. We identify a subdomain in the N-terminus that is highly conserved and when mutated significantly reduces Cdx2 inhibition of b-catenin/TCF transcriptional activity. Mutation of this subdomain also abrogates Cdx2's anti-proliferative effects in colon cancer cells. In summary, we conclude that Cdx2 binds b-catenin and disrupts the b-catenin-TCF complex. Considering the pivotal role of b-catenin/TCF activity in driving proliferation of normal intestinal epithelial and colon cancer cells, our findings suggest a novel mechanism for Cdx2-mediated regulation of Wnt/b-catenin signaling and cell proliferation.
Introduction
Despite an intense research effort, colon cancer remains a major cause of cancer morbidity and mortality worldwide. Much has been learned about the sequence by which most colorectal cancers arise from normal epithelium. This progression has been termed the adenoma-carcinoma sequence (1) . Progression along this pathway to cancer occurs through the accumulation of multiple somatic mutations, ultimately leading to malignant transformation and the formation of an invasive colon cancer.
One of the more important pathways mutated in the progression to colorectal cancer is the Wnt/b-catenin/T-cell factor (TCF) pathway. When the Wnt receptor is activated, the b-catenin protein is stabilized and translocates to the nucleus where it partners with a TCF/lymphocyte enhancer factor (LEF) family member to bind DNA and activate target gene expression. Mutations in this pathway lead to the stabilization of intracellular b-catenin and unrestricted activation of target genes (2, 3) . Aberrant activity from the Wnt/b-catenin/TCF pathway is nearly always present in human colon cancers. However, signaling from this pathway is also required to maintain the proliferative compartment of normal intestinal crypts (4) . It remains an open question as to how this critical pathway is constrained in the normal intestine to prevent neoplasia.
As with the process of colon carcinogenesis, the molecular mechanisms governing development and differentiation of the intestinal epithelium are becoming understood. One important factor promoting differentiation is the homeodomain protein Cdx2 (5) . Cdx2 is a transcription factor required for the intestine-specific expression of a number of genes (6) (7) (8) (9) (10) . Cdx2 is required for normal intestinal cell development (11) and also promotes the morphologic maturation of intestinal epithelial cells (6, 12, 13) . Observations from a number of laboratories suggest that Cdx2 expression can regulate epithelial cell proliferation and in certain contexts can limit tumor development (14) (15) (16) . However, the mechanism governing this effect is unknown.
Studies from our laboratory have investigated this question. In previous studies, we determined that colon cancer cell proliferation was reduced and b-catenin/TCF transcriptional activity was inhibited by the expression of Cdx2 (17, 18) or the closely related homologue Cdx1 (17) (18) (19) (20) . Cdx1 or Cdx2 expression resulted in diminished expression of the Wnt target genes LEF-1, Cyclin D1 and c-Myc, as well as a reduction of cell proliferation. This finding has subsequently been confirmed by others in endometrial carcinoma cells (21) . In both studies, Cdx expression was associated with diminished b-catenin responsiveness of Wnt targeted promoters like cyclin D1, Cdx1 and p14ARF (17, 21) . However, in neither study was the mechanism whereby Cdx2 inhibits Wnt/b-catenin/TCF transcriptional activity elucidated. In the present study, we extend these observations by demonstrating that Cdx2 inhibition of b-catenin/TCF transcriptional activity does not require Cdx2 transactivator function. Rather, Cdx2 directly binds b-catenin and disrupts the b-catenin-TCF protein complex. This is a novel and unexpected function for Cdx2, suggesting that Cdx2's contributions to intestinal cell differentiation may include other functional protein-protein interactions beyond those required for its well-studied role as an intestine-specific transcription factor.
Materials and methods
Cell culture and transfections DLD1, Caco2 and 293T cells were obtained from the American Type Culture Collection or the Cell Center (University of Pennsylvania). Cells were all maintained as recommended by the American Type Culture Collection.
The 293T cells were transfected using FuGENE 6 (Roche Diagnostics GmbH, Roche Applied Science, Mannheim, Gemany). Cells were grown to 50-70% confluence and were transfected with 100 ng of pRC expression vectors, 100 ng of TOPFLASH and 200 ng of pCineo-S33Y-b-catenin (both kindly provided by Dr Ken Kinzler, The Johns Hopkins University), 1 ng of pRL-CMV Renilla control reporter (Promega, Madison, WI) and 700 lg of pCR2.1 (Stratagene, La Jolla, Calif) as carrier. Expression plasmids for FlagCdx2 and Flag-Cdx1 were described previously (10, 22) . For studies examining sucrase isomaltase (SI) promoter activation (6, 23) , 100 ng of the SI-luc reporter was transfected in place of TOPFLASH. Media were changed at 24 h, and at 48 h, the cells were harvested. Luciferase assays were performed using the dual luciferase assay kit (Promega). Luciferase activity was normalized to both total protein concentration and the transfection control Renilla luciferase levels. Cellular DNA content was quantified as described (20) . DLD1 cells were transfected by electroporation as described previously (17, 20) . Statistical testing was by analysis of variance and Tukey rank mean testing for all assays.
The DNA content studies by flow cytometry were performed exactly as described (17) .
For the b-catenin/TCF co-precipitation study, 293T cells were transfected as before, using a c-Myc-tagged TCF4 along with pCineo-S33Y-b-catenin (both kindly provided by Ken Kinzler, Johns Hopkins) along with our Cdx2 expression vectors. At 48 h post-transfection, cells were harvested and lysed in mammalian protein extract reagent (M-PER; Pierce Protein Research Products, Thermo Scientific, Rockford, IL). Immunoprecipitation was performed by using the ProFound c-Myc-Tag IP/CoIP kit according to the manufacturer's instructions. The precipitated products were analyzed by western blotting by using an anti-b-catenin polyclonal antibody (sc-7199; Santa Cruz Biotechnology, Santa Cruz, CA). For the b-catenin-Cdx2/1 co-immunoprecipitation, two approaches were used. One was to use Flag-tagged Cdx proteins. The 293T cells were transfected as before with Flag-Cdx and pCineo-S33Y-b-catenin. At 48 h, cells were harvested and lysed in lysis buffer containing 50 mM TrisHCl, pH 7.4, 150 mM NaCL, 1 mM ethylenediaminetetraacetic acid and 1% Triton X-100. Immunoprecipitation was performed by using FLAG-tagged protein immunoprecipitation kit (Sigma). For the Caco2 cell study, the cells were cultured to total confluence for 7 days, then harvested and lysed in lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40 and 0.1% sodium deoxycholate. Immunoprecipitation was performed by using monoclonal Cdx2 (MU392A-UC; BioGenex Laboratories, San Ramon, CA) and Protein G-Agarose (Roche). The precipitated products were analyzed by western blotting by using an anti-b-catenin polyclonal antibody (sc-7199; Santa Cruz Biotechnology). CatCLEF and VP16-LEF were transfected as described. CatCLEF was kindly provided by Brigid Hogan, Duke University (26, 27) . VP16-LEF was generously provided by Peter Klein, University of Pennsylvania (17) .
Serial and site-directed mutagenesis
To map the region in Cdx2 protein responsible for the inhibitory effect on the b-catenin/TCF transcriptional activity, we initially used polymerase chain reaction-truncated mutants that were subsequently subcloned into the pRC-CMV vector. Primers utilized for this are listed in supplementary Table S1 (Supplementary Table S1 is available at Carcinogenesis Online) or published elsewhere (24) . After determining that the protein region between amino acids 15 and 50 was required for the inhibitory effect, we used the QuikChange II site-directed mutagenesis kit (Stratagene) to generate five mutants within this region in which seven sequential amino acids were mutated to an alanine or glycine. All mutants were fully sequenced to confirm accuracy of the mutagenesis. The sequence of the primers used for the mutagenesis is listed in Table S1 .
Glutathione-S transferase pull-down For in vitro binding assay, 35 S-labeled Cdx1, Cdx2 and TCF4 proteins were produced in vitro by using the TNT T7 Quick-coupled transcription/translation system (Promega). Bacterial expression constructs pGEX-KT/CAG456-b-catenin (kindly provided by Dr David L. Rimm, Yale University) directed the synthesis of Glutathione-S transferase (GST)-b-catenin fusion protein.
Equal amounts of GST-b-catenin fusion protein or GST alone, as a negative control, was incubated with in vitro synthesized 35 S-labeled Cdx1, Cdx2 or Tcf4 in HND buffer (10 mg/ml Bovine Serum Albumin, 20 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 50 mM NaCl, 0.1% Nonidet P-40, 5 mM Dithiothreitol) on a rotator for 1 h at 4°C. After washing the beads four times in 500 ll of MTPBS buffer (phosphate buffered saline þ 0.1% Nonidet P-40), bound 35 S-labeled proteins were separated on sodium dodecyl sulfatepolyacrylamide gel electrophoresis and visualized by autoradiography.
Results
Cdx2 inhibition of b-catenin/TCF is sensitive to protein levels in human colon cancer cells We have demonstrated previously that expression of the homeodomain transcription factor Cdx2, or the closely related homologue Cdx1, could inhibit Wnt/b-catenin/TCF signaling in many cell types including human colon cancer cells (HCT116, DLD1, HT-29 and Colo 205), immortalized and transformed 293T cells and in Xenopus embryos (12, 17, 19, 20) . Others have reported a similar effect of Cdx2 in human endometrial cancers (21) . In our last published study, we noted unexpectedly that Cdx1 was a more potent inhibitor of b-catenin/TCF transcriptional activity than its homologue Cdx2 in colon cancer cells (17) . This was unexpected because Cdx2 is typically a better transcriptional activator of intestine-specific genes (data not shown). In the same study, we also noted that in non-colon cancer models (Xenopus embryos and 293T cells), Cdx2 was a better inhibitor of b-catenin/TCF transcriptional activity. To understand these contrasting observations better, we directly compared Cdx1 and Cdx2's ability to activate SI promoter activity (a canonical Cdxresponsive reporter) (6, 14, 23) with their ability to inhibit the b-catenin/ 
TCF reporter TOPFLASH (28) in both DLD1 cells (a human colon cancer cell line) and 293T cells (a non-colon cancer cell line).
We observed that Cdx2 remained a potent activator of the SI promoter in DLD1 cells, nearly 10-fold greater than Cdx1 ( Figure 1A ). This is typical for most colon cancer cells and may be due to Cdx2's ability to synergize with co-factors GATA4 and HNF-1a (23, 29) . However, despite this significant activity, Cdx2 was less effective than Cdx1 at inhibiting TOPFLASH in those same cells. In the 293T cells, a different pattern emerged. Both Cdx1 and Cdx2 are potent activators of the SI reporter construct ( Figure 1A ). Moreover, both are potent inhibitors of TOPFLASH reporter activity ( Figure 1A ). However, Cdx2 is a much better inhibitor of TOPFLASH than Cdx1 (99.5% reduction versus 92% inhibition, respectively). This confirms our earlier findings that in non-colon cancer cells, Cdx2 is a more potent inhibitor of Wnt/b-catenin/TCF than Cdx1 (17) .
The vectors we used to express Cdx1 and Cdx2 included a Flag-tag at the Cdx N-terminus. We next compared Cdx1 and Cdx2 protein levels using a Flag antibody. Transfecting equal amounts of Cdx1 and Cdx2 expression vector DNA did not yield equal amounts of Cdx protein.
Greater protein levels of Cdx1 resulted from the otherwise equivalent transfection in both cell lines ( Figure 1B) . In 293T cells, Cdx1 and Cdx2 protein levels could be matched by doubling the amount of the Cdx2 expression vector transfected. However, in DLD1 cells, increasing the amount of Cdx2 expression vector by as much as 8-fold did not yield significantly greater Cdx2 levels. We suspect that this limitation of Cdx2 protein levels in colon cancer cells may explain why Cdx2 is a less effective inhibitor of TOPFLASH than Cdx1. We conclude that Cdx2-mediated inhibition of Wnt/b-catenin signaling is mechanistically distinct from its activation of transcriptional targets. Moreover, this mechanism is very sensitive to Cdx2 protein levels, much more so than the classic transcriptional activator function.
The classical transcriptional activation domain is not required for Cdx2-mediated inhibition of Wnt/b-catenin transcriptional activity Since it appeared that SI induction and TOPFLASH inhibition by Cdx2 were mechanistically different, we next tested several Cdx2 mutants for their ability to activate the SI reporter or inhibit TOP-FLASH. The response of the SI reporter to the Cdx2 mutants was as reported previously (24) , while the response of TOPFLASH was revealing. Cdx2 is a known phosphoprotein, and phosphorylation at Ser60 has been associated with reduced SI promoter activation (24) . While mutation of this site as well as several other serine phosphorylation sites (Cdx2 S60 and Cdx2 S56,57,58,60 ) did appear to weakly increase SI promoter luciferase activity, the difference was not statistically significant. Also, these mutations had no significant effect upon TOPFLASH reporter inhibition (Figure 2A) . Deletion of the Cdx2 C-terminus (Cdx2CD) reduced SI reporter activity by $50%. This was unexpected based on previous studies in NIH3T3 cells that found no effect from the C-terminus truncation on SI reporter activation (24) . Studies following up on this modest reduction are planned. However, this truncation had no effect on TOPFLASH inhibition (Figure 2A ). In contrast, deletion of Cdx2's N-terminus (Cdx2ND), containing the transcription activation domain, completely abrogated both SI activation and TOPFLASH inhibition. Surprisingly, though, when we deleted just the canonical transcription activation domain between amino acids 55 and 136 (Cdx2D55-136) (24) while we completely abrogate Cdx2 transcriptional activity and SI promoter induction, this truncation has no effect on TOPFLASH inhibition. The Cdx2D55-136 mutant remained equal to the wild-type Cdx2 protein with regard to TOPFLASH inhibition ( Figure 2A ).
To better define the region of Cdx2 required for b-catenin/TCF inhibition, we generated additional truncation mutants by polymerase chain reaction mutagenesis. We separately deleted the first 15 amino acids (Cdx2D15), 50 amino acids (Cdx2D50) and the region between amino acids 140 and 180 (Cdx2D140-180; Figure 2B ). All three mutants were Flag tagged and yielded proteins detectable by western blot. Moreover, all three were fully localized to the nucleus post-transfection (data not shown). Surprisingly, all three Cdx2 mutants had significantly diminished capacity to activate the SI reporter despite the fact that these deletions fell outside the transcription activation domain (24) . In contrast, TOPFLASH inhibition was largely maintained by the mutant constructs. Both the Cdx2D15 and Cdx2D140-180 mutants fully S56,57,58,60 were probed using a polyclonal antibody against the Cdx2 C-terminus. a, significantly differs from Cdx2 wild-type, P , 0.001; b, significantly differs from Cdx2 wild-type and Empty vector, P , 0.05; c, Differs from Empty vector and Cdx2D50, P , 0.01.
Ã Significantly differs from empty vector control, P , 0.001.
Cdx2 disrupts the b-catenin-TCF protein complex inhibited the TOPFLASH reporter ( Figure 2B) . However, the Cdx2D50 mutant lacked any ability to limit TOPFLASH and was no different from the empty vector construct. Taken as a whole, these studies suggest that a subdomain located between amino acids 15 and 50 in Cdx2 is required for b-catenin/TCF inhibition.
Cdx2 expression disrupts the b-catenin-TCF protein complex A number of mechanisms have been reported that limit Wnt signaling. These mechanisms either block signaling by the receptor (30,31) , regulate b-catenin protein levels (32), inhibit its translocation to the nucleus (33, 34) , disrupt the b-catenin-TCF protein complex (35, 36) , or block b-catenin/TCF binding to DNA (37, 38) . In our prior studies, we had demonstrated that Cdx expression did not significantly alter b-catenin protein levels or its ability to localize to the nucleus (17) . We therefore considered other mechanisms.
To determine whether Cdx2 was a competitive inhibitor of b-catenin/ TCF by either binding TCF-responsive elements or blocking (through other means) TCF-binding DNA targets, we co-transfected two TCF-LEF fusion proteins along with Cdx2 into 293T cells. VP16-LEF is a fusion of the viral VP16 transactivation domain with the DNAbinding domain from LEF-1 (17) . CatCLEF fuses the b-catenin transactivation domain to the LEF-1 DNA-binding domain (26, 27) . Cdx2 co-expression could not diminish TOPFLASH activation by either of these two chimeric proteins ( Figure 3A) . Thus, Cdx2 cannot block TCF/LEF binding to DNA, suggesting that this is not the mechanism by which Cdx2 inhibits Wnt/b-catenin. Cdx2's failure to inhibit either chimera suggested that Cdx2 functions at an earlier step, possibly by inhibiting b-catenin-TCF complex formation.
We tested for this using a myc-tagged TCF4 in 293T cells. After cotransfection of myc-TCF4 along with the S33Y-b-catenin mutant that is stabilized from GSK-3b phosphorylation and proteosome degradation, we could immunoprecipitate the myc-tagged protein and identify robust b-catenin co-precipitation ( Figure 3B ). Co-transfection of as little as 10 ng of a Cdx2 expression vector nearly completely blocked this interaction and increasing it to 25 ng completely abrogated the complex formation. This was not due to effects on b-catenin or myc-TFC protein levels, as evidenced by controls. Similar results were obtained in DLD1 cells (Figure 3C ), suggesting that this disruption is a general phenomenon. Moreover, when we tested the Cdx2 truncation mutants in this assay, we noted that the ability to disrupt the b-catenin-TCF complex correlated with the inhibition of TOPFLASH activity ( Figure 3D ). Wild-type Cdx1 and Cdx2 proteins, as well as truncation mutants Cdx2D15, Cdx2D55-136 and Cdx2D140-180 completely blocked b-catenin co-precipitation with myc-TCF, whereas the Cdx2ND and Cdx2D50 mutants did not. In summary, Cdx2 expression blocks Wnt signaling by disruption of the b-catenin-TCF complex.
The homeodomain transcription factor Cdx2 binds b-catenin These findings together suggest that Cdx2 might bind b-catenin or TCF4 to inhibit complex formation and transcriptional activity. To investigate for this, we transfected Flag-Cdx2 along with S33Y-b-catenin into 293T cells and immunoprecipitated either with antiFlag or anti-b-catenin. We found that b-catenin binds with Cdx2, as both proteins are precipitated when either is pulled down ( Figure 4A ). However, Cdx2 did not co-precipitate with the myc-tagged TCF4 vector (data not shown). Similarly, using endogenously expressed proteins, immunoprecipitation of CDX2 from 7-day post-confluent Caco2 cells also pulled down b-catenin ( Figure 4B ). Thus, the interaction between Cdx and b-catenin is not due to transfectionmediated protein over-expression and can be established using endogenous CDX2 and b-catenin proteins.
To determine if Cdx2 directly binds b-catenin, we performed GST pull-down studies. GST-b-catenin could not pull-down 35 S-labeled Cdx2 protein, although an interaction with a control 35 S-labeled TCF4 was established ( Figure 4C ). The 35 S-labeled Cdx2 did interact with a positive control GST-UBC9, confirming that the in vitro translated Cdx2 protein and assay conditions were functioning. Moreover, the in vitro synthesized Cdx2 could not disrupt the GST-b-catenin/ 35 S-TCF4 interaction, as pre-incubation of GST-b-catenin with increasing amounts of in vitro synthesized Cdx2 had no impact on the 35 S-TCF4 pull-down ( Figure 4D) . Together with the cell culture studies, these observations suggest that Cdx2 requires another factor or protein modification in order to bind b-catenin.
Cdx2 transcriptional activity and TOPFLASH suppression requires a highly conserved subdomain located in the N-terminus Using truncation mutants, we grossly mapped a subdomain required for the inhibition of b-catenin/TCF to between amino acids 15 and 50 ( Figure 2 ). To better define this region, we generated a series of five site-directed mutants. Seven amino acids in each mutant were mutated to alanine or glycine ( Figure 5A ). All mutants were carefully sequenced, and production of nuclear-localizing proteins of appropriate sizes was confirmed by western blot and immunofluorescence (data not shown). We then utilized these mutants in transient transfection studies with TOPFLASH and SI reporters in 293T cells, as was done before. Mutant 1 behaved much as the wild-type Cdx2 protein ( Figure 5B ). In contrast, mutants 2, 3, 4 and 5 were all significantly different from Cdx2 wild-type and empty expression vector controls (P , 0.05). Mutant 4, in particular (amino acids 37-43), had very significant findings. Mut4 was distinctly different from all other constructs used in this study, including the other mutants (P , 0.05). Mut4 transactivation of the SI reporter was only 20% of the wild-type protein ( Figure 5B ). Moreover, Mut4 inhibition of TOPFLASH was diminished by one-third ( Figure 5B ). These findings indicate that a subdomain critical to Cdx2 transcriptional activity and TOPFLASH suppression is located between amino acids 23 and 50, with the most critical region between amino acids 37 and 43.
To determine whether this region of Cdx2 is conserved in any fashion, we aligned Cdx2 amino acid sequences using MacVector software (Oxford Molecular Group, Campbell, CA). We noted that the Cdx2 sequences across highly diverged species remained remarkably conserved ( Figure 5C ). This high-degree of conservation has been noted by others (5) . However, the amino acid sequence between amino acids 25 and 45 is nearly perfectly conserved. More remarkably, when we aligned the murine Cdx2 sequence with Cdx1 and Cdx4 sequences, we found a region between amino acids 33 and 43 that remained highly conserved between these more distant Caudal homologues and paralogues ( Figure  5C ). In light of the fact that Cdx1 is also an effective inhibitor of Wnt/ b-catenin/TCF4 signaling, we suspect that the conserved domain shared by these factors plays a critical role in that process.
Lastly, to establish a functional role for this domain in the inhibition of cell proliferation, we transfected the truncation mutants along with Cdx2Mut4 into HCT 116 cells. Previously, we had shown that transfection of Cdx1 or Cdx2 into these cells inhibited TOPFLASH reporter activity and induced a G 0 /G 1 accumulation of cells, consistent with a growth arrest (17). As we had reported previously, the wild-type Cdx2 protein induces an 18% increase in G 0 /G 1 cells ( Figure 6A ). The Cdx2 mutants Cdx2D15, Cdx2D55-136 and Cdx2D140-180, which efficiently inhibited TOPFLASH and disrupted the b-catenin-TCF complex, induced a similar level of G 0 /G 1 accumulation of cells. In contrast, neither Cdx2ND, Cdx2D50 nor Cdx2Mut4 were significantly different from each other or from the empty vector control ( Figure 6A ). This further substantiates that Cdx2 inhibition of TOP-FLASH correlates with the inhibition of cell proliferation and that a subdomain critical for this effect is located in the protein's N-terminus and centered between amino acids 36 and 43. We conclude that a subdomain important both for normal Cdx2 transcriptional activity and the Cdx2 disrupts the b-catenin-TCF protein complex inhibition of b-catenin/TCF4 transcriptional activity and cell proliferation is centered between amino acids 33 and 43.
Discussion
One important question that has not been well studied to date is how developmental mechanisms that promote intestinal cell differentiation can regulate the Wnt/b-catenin/TCF pathway. The Caudal related homeodomain protein Cdx2 is an intestine-specific transcription factor that directs the expression of the intestinal cell phenotype by enhancing the expression of numerous intestine-specific genes and promoting the emergence of a mature, columnar cell morphology (5, (10) (11) (12) (13) (14) 18) . We and others have demonstrated previously that Cdx1 or Cdx2 expression could reduce colon cancer cell proliferation by inhibiting b-catenin/TCF transcriptional activity (17, (19) (20) (21) . This was associated with the diminished expression of the Wnt target genes LEF-1, Cyclin D1 and c-Myc, as well as a reduction of b-catenin responsiveness of Wnt targeted promoters like cyclin D1, Cdx1 and p14ARF (17, 21) . The present study advanced this work by identifying a mechanism for this effect, namely that these important developmental regulators may antagonize Wnt/b-catenin/TCF transcriptional activity by directly binding b-catenin and disrupting the b-catenin-TCF protein complex. This is a very novel finding and suggests that Cdx2 may influence development, gene expression patterns and cell differentiation by means other than as a transcription activator.
Cdx2-mediated inhibition of b-catenin/TCF is molecularly distinct from its role as a transcriptional activator Several lines of data strongly suggest that the mechanisms whereby Cdx2 induces SI promoter activity and inhibits b-catenin/TCF are quite different. Previous studies by us in colon cancer cell lines as well as non-colorectal cancer systems suggested that there was a disconnect between the two processes. In the present study, using Flagtagged Cdx1 and Cdx2 proteins, we determined that the inhibition of TOPFLASH was very dependent upon protein levels, whereas SI activation was not. Studies with Cdx2 truncation mutants firmly R.-J. Guo et al. established that these were distinctly different processes since Cdx2 transcriptional activity was not required for TOPFLASH inhibition or the reductions in cell proliferation, but is necessary for SI induction. Together, these findings establish that Cdx2 inhibition of b-catenin/ TCF and transactivation of target genes like SI utilizes distinctly different mechanisms. These are important differences that colon cancer cells appear able to exploit, specifically suppressing TOP-FLASH inhibition while maintaining SI activation. This undoubtedly has important implications for colon carcinogenesis. These observations also have clear mechanistic implications we explored in the subsequent studies described above.
A model for Cdx2 inhibition of Wnt/b-catenin/TCF signaling Our findings have significantly extended our previously published work and the work of others which first identified the inhibitory effect of Cdx1 and Cdx2 upon Wnt/b-catenin/TCF signaling (17, 19, 20) . Our data argue that the inhibitory effect is mediated by the Cdx2 protein interacting with b-catenin, leading to disruption of the b-catenin-TCF complex ( Figure 6B ). However, since we can only demonstrate this interaction in vivo, we believe that another protein factor or some post-translational modification of Cdx2 or b-catenin is required to promote this interaction. We are presently pursuing studies to identify this unknown factor. Moreover, it is interesting to note that while classic Cdx2 transcriptional activity is not required for the inhibition of b-catenin/TCF, every Cdx2 mutation that disrupts TOPFLASH inhibition also significantly degrades Cdx2 transcriptional activity. Therefore, our work yields novel insights not only into the regulation of Wnt/b-catenin/TCF activity by Cdx2, but the regulation of classic Cdx2 transcriptional activity as well. Although Wnt signaling is known to inhibit the actions and expression of homeodomain transcription factors (39, 40) , to our knowledge, this is the first example of a homeobox protein inhibiting b-catenin-TCF by a protein interaction. These studies also shed important new light on a paradox regarding the role of Cdx2 in human colorectal cancer. Historically, Cdx2 was thought to be a 'tumor suppressor' due to its ability to reduce proliferation of some colon cancer cells and its reported loss in human colon polyps and cancers (14, 41, 42) . Most importantly, transgenic mice heterozygous for a deletion of Cdx2 formed many more polyps than non-transgenic controls when crossed with the tumorigenic Apc þ/D716 mice or when treated with the carcinogen azoxymethane (15, 16) . However, several recent studies have begun to cast doubt on Cdx2 as a classic tumor suppressor, with at least two studies, suggesting that Cdx2 may possess tumorigenic properties (43) (44) (45) . In these studies, it is suggested that Cdx2 expression enhances cell survival, possibly by inducing the expression of the anti-apoptotic Bcl-2 protein. If, indeed, Cdx2 possesses both tumorpromoting and inhibitory properties, our studies suggest that colon cancer cells may be able to separate them, retaining the former whereas disabling the latter.
The antitumor property studied here, the anti-proliferative effect of Cdx2, is dependent upon a protein-protein interaction between Cdx2 and b-catenin that disrupts the pro-proliferative b-catenin-TCF complex. This is probably a stochiometric relationship and, therefore, processes that increase b-catenin levels or diminish Cdx2 can promote transformation. Thus, we see b-catenin levels increased and Cdx1 protein expression silenced in the majority of human colon cancers (46, 47) . Moreover, the Cdx2 protein appears to be less stable in colon cancer cells due to ubiquination and proteosome degradation (48, 49) . The ultimate result is diminished capacity for Cdx-mediated inhibition of b-catenin/TCF while retaining significant Cdx2 transcriptional activity. This may then serve to promote carcinogenesis by preserving the expression of anti-apoptotic factors like Bcl-2 (45, 50) .
In summary, we establish a novel mechanism by which the intestine-specific transcription factor Cdx2 inhibits intestinal cell proliferation and b-catenin/TCF function. An evolutionarily conserved subdomain localized to the N-terminus of Cdx2 mediates its interaction with b-catenin. This interaction is capable of disrupting b-catenin binding to TCF, leading to loss of the proliferative Wnt/b-catenin/TCF stimulus. We conclude that Cdx2 inhibition of Wnt/b-catenin/TCF signaling and proliferation in colon cancer and intestinal epithelial cells is dependent upon Cdx2 binding b-catenin and disrupting its interaction with the DNA-binding TCF factor family.
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